 |
 |
9846: Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI) DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program EAY131 (MATCH): Molecular Analysis for Therapy Choice S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (For patients that did not have a match to a [...]
Two physicians have joined the radiation oncology team at West Michigan Cancer Center & Institute for Blood Disorders (WMCC), a collaboration of Ascension Borgess and Bronson Healthcare Group. Daniel Chamberlain, MD, is WMCC’s new division chief of radiation oncology. Dr. Chamberlain has 14 years’ experience in clinical and academic medicine, most recently as a faculty member [...]
West Michigan Cancer Center & Institute for Blood Disorders (WMCC), a collaboration of Ascension Borgess and Bronson Healthcare Group, has named Bridget VandenBussche to lead the organization as Interim Executive Director. VandenBussche takes the helm of WMCC after two and a half years as director of quality improvement and risk. She has been with the [...]
KALAMAZOO, MICHIGAN —Care for women with breast cancer has made tremendous strides over the past decade and that includes guidance on how to move forward with life after treatment. One of the most beneficial tools provided to breast cancer patients at the West Michigan Cancer Center & Institute for Blood Disorders (WMCC) is a survivorship [...]
West Michigan Cancer Center & Institute for Blood Disorders (WMCC), a collaboration of Borgess / Ascension and Bronson Healthcare Group, is pleased to announce the addition of three providers. Casey Hay, MD is a gynecologic oncologist with 7 years’ experience in clinical medicine. Dr. Hay earned her medical degree [...]
FOR IMMEDIATE RELEASE CONTACT: Lynne Emons Phone: 269-384-8624 Email: Lemons@wmcc.org West Michigan Cancer Center & Institute for Blood Disorders in Kalamazoo, Michigan has been granted a three-year/full accreditation designation by the National Accreditation Program for Breast Centers (NAPBC), a program administered by the American College of Surgeons. Accreditation by the NAPBC is only given to [...]
A071401: Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations N0577: CODEL: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination [...]
WMCC radiation therapy staff is ready to begin treatments using the newly installed TrueBeam linear accelerator. Back row, left to right: Mazen Mislmani, MD; Jeff Tkac; Jeffrey Radawski, MD; Chen Chen; Kris Lutz. Front row, left to right: Linda Grossheim, MD; Renu Sharma; Lori Burleigh; Holly Henderson; Sherri Jipping. KALAMAZOO, MICHIGAN —West Michigan [...]
KALAMAZOO, Mich.–West Michigan Cancer Center & Institute for Blood Disorders (WMCC) and Sturgis Hospital have formed a clinical partnership that will expand patients’ access to advanced cancer care, innovative clinical trials and survivorship resources in St. Joseph County. “We’re very pleased to collaborate with the West Michigan Cancer Center,” said Rob LaBarge, Sturgis Hospital President [...]
West Michigan Cancer Center & Institute for Blood Disorders, a collaboration of Borgess Health and Bronson Healthcare Group, is pleased to welcome three new providers. Dustin Bivins, DO is a hematologist and medical oncologist. Dr. Bivins earned his medical degree from the Chicago College of Osteopathic Medicine in Downers Grove, IL. He completed his residency [...]